SCHEMBL2332913

SCHEMBL2332913

CCOC(=O)CN(C)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.65
ALOX15 P16050 1/20 0.63
GAA P10253 3/20 0.52
TDP1 Q9NUW8 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA3 P07451 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA13 Q8N1Q1 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
POLB P06746 2/20 0.49
KMT2A Q03164 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673729 0.88 ALDH1A1 (0.56) ADRB2ALOX15GAAALDH1A1KMT2A
SCHEMBL6501728 0.87 KMT2A (0.59) ADRB2ALOX15GAAALDH1A1CA12
SCHEMBL6500736 0.85 KMT2A (0.56) ADRB2ALOX15GAAALDH1A1POLB
SCHEMBL11482764 0.85 KMT2A (0.53) ADRB2ALOX15GAAALDH1A1POLB
SCHEMBL11580067 0.85 GAA (0.58) ADRB2ALOX15GAATDP1ALDH1A1
SCHEMBL26247562 0.82 MAPT (0.61) ADRB2ALOX15GAATDP1ALDH1A1
SCHEMBL15705731 0.81 GAA (0.54) ADRB2ALOX15GAATDP1CA12
SCHEMBL11579297 0.80 POLB (0.64) ADRB2GAATDP1ALDH1A1CA12
SCHEMBL6384244 0.79 ALDH1A1 (0.56) ADRB2ALOX15GAATDP1ALDH1A1
SCHEMBL7928510 0.79 LMNA (0.50) ADRB2ALOX15GAATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ADRB2 938/4885ALOX15 3384/4885GAA 1320/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ADRB2 938/4885ALOX15 3384/4885GAA 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.